Skip to content
OpenCapital
Get started

Relmada Therapeutics, Inc. RLMD Increase (Decrease) in Prepaid Expense

Increase (Decrease) in Prepaid Expense at other companies

Nuvation Bio logo
Nuvation BioNUVB
——
XER
Xeris Biopharma Holdings, Inc.XERS
——

Other financials

Income statement

See full
Operating income-$19.5M-6.8%
Net income-$19.1M-8.5%
EPS (diluted)-$0.22+62.1%

Balance sheet

See full
Cash & equivalents$9.8M+750%
Total debt$104.1M-40.4%
Total equity$218.7M+875%
Total assets$235.4M+750%

Cash flow

See full
Operating cash flow-$15.1M+16.6%

Valuation

See full
Market cap$677.17M+2,907%

Returns & leverage

See full
Return on equity-48.8%-20.0pp
Debt / equity0.9×0.0×
Current ratio18.3×+13.0×

Where this comes from

Reported directly by Relmada Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInPrepaidExpense.

The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Relmada Therapeutics, Inc.'s increase (decrease) in prepaid expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Relmada Therapeutics, Inc.'s increase (decrease) in prepaid expense?
Relmada Therapeutics, Inc. (RLMD) reported increase (decrease) in prepaid expense of $402.43K in Q1 2026.
How has Relmada Therapeutics, Inc.'s increase (decrease) in prepaid expense changed year-over-year?
Relmada Therapeutics, Inc.'s increase (decrease) in prepaid expense increased by 238.7% year-over-year, from -$290.05K to $402.43K.